The relationship between drug impurities and drug safety is a complex relationship that is affected by many factors.Usually, most of the impurities in drugs have potential biological activity, and some even interact with drugs to affect the efficacy and safety of drugs.

Considering the influence of impurities in the drug, the smaller the content of impurities, the better, but if the impurities are completely removed, it will inevitably cause difficulties in production operations, increase production costs, reduce effectiveness, and increase the burden on patients e......

The global pharmaceutical intermediates market is expected to reach US$ 37,290.33 million in 2028 from US$ 27,356.70 million in 2020. The market is estimated to grow with a CAGR of 3.95% during 2020-2028. Countries in Asia Pacific are emerging as attractive outsourcing locations for pharmaceuticals ......

Special Materials Company (SMC) reports the successful startup of its new commercial scale alkyl phosphines unit at its Changshu New Tech JV factory in Changshu, Jiangsu Province China. SMC's investment in the specialized APT (Advanced Phosphine Technology) shall bring a new reliable supply of alkyl......

Sanofi announced that the Phase 3 PEGASUS trial of rilzabrutinib for pemphigus, a rare autoimmune skin disease, failed to meet its primary or key secondary endpoint. But the company noted that the drug's safety profile in trials was consistent with previous studies. Rilzabrutinib has previously bee......

Incyte Inc. announced that the U.S. Food and Drug Administration (FDA) has approved its JAK inhibitor Jakafi (Ruxolitinib) for the treatment of chronic graft-versus-host disease (GVHD) in adults and children 12 years and older. These patients had received one or two systemic treatments.